Proton-pump inhibitor proton-pump.com

Additional information:
Chemical dimerizer used in auxin-inducible degron (AID) systems. Induces degradation of a target protein tagged with the auxin-receptor F-box protein Tir1 E3 ligase AID in human colorectral cancer and mouse ES cells or tagged with AFB2 in A431 cells. Endogenous plant hormone.|Product information|CAS Number: 87-51-4|Molecular Weight: 175.18|Formula: C10H9NO2|Synonym:|indolylacetic acid|1H-Indole-3-acetic acid|indoleacetic acid|heteroauxin|IAA|Chemical Name: indole-3-acetic acid|Smiles: OC(=O)CC1=CNC2=CC=CC=C21|InChiKey: SEOVTRFCIGRIMH-UHFFFAOYSA-N|InChi: InChI=1S/C10H9NO2/c12-10(13)5-7-6-11-9-4-2-1-3-8(7)9/h1-4,6,11H,5H2,(H,12,13)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO: 35 mg/mL(199.79 mM). Water: undefined.|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Eugenol} medchemexpress|{Eugenol} Apoptosis|{Eugenol} Purity & Documentation|{Eugenol} In Vitro|{Eugenol} custom synthesis|{Eugenol} Autophagy} |Shelf Life: ≥12 months if stored properly.PMID:36628218 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Indole-3-acetic acid (IAA) induces cytotoxicity in fibroblasts, neutrophils, and several cancer lineages in vitro.|In Vivo:|IAA administration in pregnant rats during days 12-14 might selectively affect the S phase neurons and lead to their apoptosis in the neuroepithelium. It induces microencephaly in rats.|References:|Furukawa S, et al. Toxicol Pathol. 2004, 32(6):659-67.Products are for research use only. Not for human use.|

Additional information:
GSK256066 is a potent and selective PDE4 inhibitor that can be given by inhalation, minimising the potential for side effects. GSK256066 demonstrated a protective effect on the EAR and LAR. GSK256066 is a slow and tight binding inhibitor of PDE4B (apparent IC(50) 3.2 pM; steady-state IC(50) Product information|CAS Number: 801312-28-7|Molecular Weight: 518.58|Formula: C27H26N4O5S|Synonym:|GSK256066|GSK-256066|GSK 256066|Related CAS Number:|801315-14-0 (HCl)|1415560-64-3 (TFA)|Chemical Name: 6-[3-(dimethylcarbamoyl)benzenesulfonyl]-4-[(3-methoxyphenyl)amino]-8-methylquinoline-3-carboxamide|Smiles: CC1=CC(=CC2=C1N=CC(C(N)=O)=C2NC1=CC(=CC=C1)OC)S(=O)(=O)C1=CC(=CC=C1)C(=O)N(C)C|InChiKey: JFHROPTYMMSOLG-UHFFFAOYSA-N|InChi: InChI=1S/C27H26N4O5S/c1-16-11-21(37(34,35)20-10-5-7-17(12-20)27(33)31(2)3)14-22-24(16)29-15-23(26(28)32)25(22)30-18-8-6-9-19(13-18)36-4/h5-15H,1-4H3,(H2,28,32)(H,29,30)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Solubility (25°C) DMSO: 5 mg/mL(9.64 mM). Water: Insoluble.|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|GSK256066 is a slow and tight binding inhibitor of PDE4B with apparent IC50 of 3.2 pM. GSK256066 is an extremely potent inhibitor of LPS-stimulated TNFα production in PBMCs with pIC50 of 11.0 and IC50 of 10 pM and human whole-blood cultures with pIC50 of 9.90 and IC50 of 126 pM. GSK256066 is highly selective for PDE4 (>3.8 × 105-fold versus PDE1, PDE2, PDE3, PDE5, and PDE6 and >2.5 × 103-fold against PDE7). GSK256066 inhibits PDE4 isoforms A-D with equal affinity.|In Vivo:|GSK256066 inhibits the LPS-induced pulmonary neutrophilia with an ED50 of 1.1 μg/kg, achieving maximal inhibition of 72% at 30 μg/kg when given in the aqueous suspension.PMID:26895888 GSK256066 inhibits the LPS-induced pulmonary neutrophilia with ED50 of 2.9 μg/kg, achieving maximal inhibition of 62% when given in the dry powder formulation. GSK256066 shows a moderate plasma clearance of 39 ml/min/kg, a moderate volume of distribution of 0.8 L/kg, and a relatively short half-life of 1.1 hour in the male CD rat. GSK256066 sustains at a high lung concentration of 2.6 μg/g after intra-tracheal administration as an aqueous suspension at a dose of 30 μg/kg in rats. GSK256066 (10 μg/kg) is administered intratracheally at different times (2, 6, 12, 18, 24, and 36 hours) before LPS administration, inhibiting LPS-Induced Pulmonary Neutrophilia in rat lipopolysaccharide (LPS)-induced models of acute pulmonary inflammation. GSK256066 (0.3–100 μg/kg) inhibits LPS-induced increases in exhaled nitric oxide with ED50 of 35 μg/kg in rat. GSK256066 (10 μg/kg) is administered half a hour before OVA administration in rat, inhibiting OVA-induced pulmonary eosinophilia with ED50 of 0.4 μg/kg. GSK256066 administered intratracheally as a dry powder blended in respiratory-grade lactose at doses of 3 to 100 μg/kg 2 hours before inhaled LPS challenge in ferrets, inhibiting LPS-induced pulmonary neutrophilia with ED50 of 18 μg/kg without inducing emetic episodes.|References:|Nials AT, et al. J Pharmacol Exp Ther, 2011, 337(1), 137-144.Woodrow MD, et al. Bioorg Med Chem Lett, 2009, 19(17), 5261-5265.Tralau-Stewart CJ, et al. J Pharmacol Exp Ther, 2011, 337(1), 145-154.Products are for research use only. Not for human use.|

Additional information:
Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus. It has a variety of pharmacological effects, including anti-cancer effects, and action as a kappa opioid receptor and u-receptor agonist.|Product information|CAS Number: 519-02-8|Molecular Weight: 248.36|Formula: C15H24N2O|Synonym:|Matridin-15-one|NSC 146051|NSC146051|NSC-146051|Chemical Name: (1R, 2R, 9S, 17S)-7, 13-diazatetracyclo[7.{{DBCO-Biotin} MedChemExpress|{DBCO-Biotin} PROTAC Linkers|{DBCO-Biotin} Epigenetics|{DBCO-Biotin} Protocol|{DBCO-Biotin} In stock|{DBCO-Biotin} manufacturer} 7.1.0, .0, ]heptadecan-6-one|Smiles: O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@H]43|InChiKey: ZSBXGIUJOOQZMP-JLNYLFASSA-N|InChi: InChI=1S/C15H24N2O/c18-14-7-1-6-13-12-5-3-9-16-8-2-4-11(15(12)16)10-17(13)14/h11-13,15H,1-10H2/t11-,12+,13+,15-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO: 49 mg/mL(197.29 mM). Water: 11 mg/mLwarmed(44.29 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Guanidine} medchemexpress|{Guanidine} Endogenous Metabolite|{Guanidine} Purity & Documentation|{Guanidine} Formula|{Guanidine} custom synthesis|{Guanidine} Epigenetics} |Shelf Life: ≥12 months if stored properly.PMID:24605203 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Matrine((+)-Matrine) is an alkaloid found in plants from the Sophora family, which has a variety of pharmacological effects, including anti-cancer effects, and action as a kappa opioid receptor agonist. Matrine significantly inhibites the growth of human non-small cell lung cancer A549 and hepatoma SMMC-7721 cells and induces apoptosis by strongly reducing the viability and the ratio of Bcl-2/Bax protein in A549 cells. matrine may stimulate the descending dynorphinergic neuron, resulting in the stimulation of kappa-opioid receptors (KORs) in the spinal cord, and this phenomenon in turn produces the antinociception in mice.|In Vivo:|LD50: Mice 157mg/kg (i.p.)|References:|Wang XY, et al. Nanfang Yike Daxue Xuebao, 2010, 30(9), 2154-2155.Higashiyama K, et al. Biol Pharm Bull, 2005, 28(5), 845-848.Zhang Y, et al. Cytotechnology, 2009, 59(3), 191-200.Products are for research use only. Not for human use.|

Additional information:
Chondroitin sulfate, one of five classes of glycosaminoglycans, has been widely used in the treatment of osteoarthritis. Chondroitin sulfate reduces inflammation mediators and the apoptotic process and is able to reduce protein production of inflammatory cytokines, iNOS and MMPs.|Product information|CAS Number: 9007-28-7|Synonym:|Chondroitin polysulfate|Chemical Name: Chondroitin sulfate|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: H2O : ≥ 50 mg/mL|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Chondroitin sulfate is a class of sulfated glycosaminoglycans that are linear polysaccharides consisting of repeating disaccharide units composed of uronic acid and N-acetylhexosamine. Several pathogens including parasites, bacteria, and viruses have been shown to utilize cell surface chondroitin sulfate chains to attach to and infect host cells[1]. Chondroitin sulfate occurs naturally in the extracellular matrix of connective tissues, e.g., bone, cartilage, skin, ligaments and tendons. Chondroitin sulfate has been shown to elicit a range of beneficial effects: anti-inflammatory effects, an increase in type II collagen and proteoglycans, a reduction in bone resorption and a better anabolic/catabolic balance in chondrocytes[2]. A large range of chondroitin sulfate concentrations has been used (e.g. 12.5 to 2000 mg/mL, but generally less than200 mg/mL) in in vitro studies. Chondroitin sulfate (200 mg/mL) decreases the chondrocyte susceptibility to single nucleotide polymorphism-induced apoptosis[3]. Chondroitin sulfate reduces inflammation mediators and the apoptotic process and is able to reduce protein production of inflammatory cytokines, iNOS, MMPs[4].|In Vivo:|The high content of chondroitin sulfate in the aggrecan plays a major part in allowing cartilage to resist tensile stresses during various loading conditions by providing this tissue with resistance and elasticity. It has been shown that chondroitin sulphate interferes with the progression of structural changes in joint tissues and is used in the management of patients with osteoarthritis[3].{{Protein G Agarose} web|{Protein G Agarose} Biological Activity|{Protein G Agarose} Formula|{Protein G Agarose} custom synthesis|{Protein G Agarose} Cancer} Chondroitin sulfate is mostly administered orally at doses ranging from 800 to 1200mg/day.{{Apocynin} MedChemExpress|{Apocynin} Metabolic Enzyme/Protease|{Apocynin} Biological Activity|{Apocynin} Formula|{Apocynin} manufacturer|{Apocynin} Cancer} Chondroitin sulfate is rapidly absorbed by the gastrointestinal tract.PMID:23833812 The absorbed chondroitin sulfate reaches the blood compartment as 10% chondroitin sulfate and 90% depolymerized low-molecular-weight derivatives[5].|References:|Mikami T, et al. Biosynthesis and function of chondroitin sulfate. Biochim Biophys Acta. 2013 Oct;1830(10):4719-33.Martel-Pelletier J, et al.Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules. 2015 Mar 6;20(3):4277-89.Monfort J, et al. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Ann Rheum Dis. 2008 Jun;67(6):735-40.Campo GM, et al. Glycosaminoglycans modulate inflammation and apoptosis in LPS-treated chondrocytes. J Cell Biochem. 2009 Jan 1;106(1):83-92.Henrotin Y, et al. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinicalrecommendations. Ther Adv Musculoskelet Dis. 2010 Dec;2(6):335-48.Products are for research use only. Not for human use.|

Additional information:
7-Methoxyisoflavone (MIF) is a potent activator of adenosine monophosphate-activated protein kinase (AMPK).|Product information|CAS Number: 1621-56-3|Molecular Weight: 252.26|Formula: C16H12O3|Chemical Name: 7-methoxy-3-phenyl-4H-chromen-4-one|Smiles: COC1=CC2OC=C(C(=O)C=2C=C1)C1C=CC=CC=1|InChiKey: IECSQLKWZBEUGA-UHFFFAOYSA-N|InChi: InChI=1S/C16H12O3/c1-18-12-7-8-13-15(9-12)19-10-14(16(13)17)11-5-3-2-4-6-11/h2-10H,1H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 25 mg/mL (99.{{Scopoletin} MedChemExpress|{Scopoletin} Apoptosis|{Scopoletin} Protocol|{Scopoletin} In Vivo|{Scopoletin} supplier|{Scopoletin} Autophagy} 10 mM; Need ultrasonic)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Tivozanib} MedChemExpress|{Tivozanib} Protein Tyrosine Kinase/RTK|{Tivozanib} Biological Activity|{Tivozanib} Data Sheet|{Tivozanib} supplier|{Tivozanib} Autophagy} |Shelf Life: ≥12 months if stored properly.PMID:24455443 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|7-Methoxyisoflavone is an isoflavone derivative and also an activator of adenosine monophosphate-activated protein kinase (AMPK). When serum-starved cells are treated with 10 % FBS in the presence of 7-methoxyisoflavone, the serum-induced decrease in AMPK phosphorylation is prevented.|References:|Hyeryoung Jung, et al. Isoflavones as modulators of adenosine monophosphate-activated protein kinase. Applied Biological Chemistry. 2016. 59, 217-225.Products are for research use only. Not for human use.|

Additional information:
GRL0617 is a potent, selective and competitive noncovalent inhibitor of SARS PLPro. GRL0617, inhibited SARS-CoV viral replication in Vero E6 cells with an EC(50) of 15 microM and had no associated cytotoxicity. The X-ray structure of PLpro in complex with GRL0617 indicates that the compound has a unique mode of inhibition whereby it binds within the S4-S3 subsites of the enzyme and induces a loop closure that shuts down catalysis at the active site.{{Emtricitabine} MedChemExpress|{Emtricitabine} Endogenous Metabolite|{Emtricitabine} Protocol|{Emtricitabine} Formula|{Emtricitabine} supplier|{Emtricitabine} Epigenetic Reader Domain} |Product information|CAS Number: 1093070-16-6|Molecular Weight: 304.{{Capsaicin} medchemexpress|{Capsaicin} Apoptosis|{Capsaicin} Biological Activity|{Capsaicin} In Vitro|{Capsaicin} supplier|{Capsaicin} Autophagy} 39|Formula: C20H20N2O|Synonym:|GRL-0617|GRL0617|GRL 0617|Chemical Name: 5-Amino-2-methyl-N-[(1R)-1-(1-naphthalenyl)ethyl]benzamide|Smiles: CC1=CC=C(N)C=C1C(=O)N[C@H](C)C1=CC=CC2=CC=CC=C21|InChiKey: UVERBUNNCOKGNZ-CQSZACIVSA-N|InChi: InChI=1S/C20H20N2O/c1-13-10-11-16(21)12-19(13)20(23)22-14(2)17-9-5-7-15-6-3-4-8-18(15)17/h3-12,14H,21H2,1-2H3,(H,22,23)/t14-/m1/s1|Technical Data|Appearance: Solid Power.PMID:35126464 |Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|References:|Chaudhuri R, Tang S, Zhao G, Lu H, Case DA, Johnson ME. Comparison of SARS and NL63 papain-like protease binding sites and binding site dynamics: inhibitor design implications. J Mol Biol. 2011 Nov 25;414(2):272-88. doi: 10.1016/j.jmb.2011.09.030. Epub 2011 Sep 29. PubMed PMID: 22004941; PubMed Central PMCID: PMC3397151.Nathan J. SchauerRobert S. MaginXiaoxi LiuLaura M. DohertySara J. Buhrlage* Advances in Discovering Deubiquitinating Enzyme (DUB) Inhibitors. Journal of Medicinal Chemistry, Articles ASAP (Perspective). Publication Date (Web):November 4, 2019DOI: 10.1021/acs.jmedchem.9b01138.Products are for research use only. Not for human use.|

Additional information:
VUN65671is a Potent Entry Inhibitor of Ebola and Marburg Virus Infections. VUN65671 was reported in Journal of Medicinal Chemistry (2020), 63(13), 7211-7225.|Product information|CAS Number: 2479465-67-1|Molecular Weight: 461.52|Formula: C25H30F3N3O2|Synonym:|VUN-65671|VUN65671|VUN 65671|Chemical Name: Benzamide,N-[4-(4-methyl-1-piperidinyl)-3-(trifluoromethyl)phenyl]-4-(4-morpholinylmethyl)-|Smiles: CC1CCN(CC1)C1=CC=C(C=C1C(F)(F)F)NC(=O)C1C=CC(CN2CCOCC2)=CC=1|InChiKey: VVJSZYWIEBDKTC-UHFFFAOYSA-N|InChi: InChI=1S/C25H30F3N3O2/c1-18-8-10-31(11-9-18)23-7-6-21(16-22(23)25(26,27)28)29-24(32)20-4-2-19(3-5-20)17-30-12-14-33-15-13-30/h2-7,16,18H,8-15,17H2,1H3,(H,29,32)|Technical Data|Appearance: Solid Power.|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Lanreotide} web|{Lanreotide} Biological Activity|{Lanreotide} Purity|{Lanreotide} supplier|{Lanreotide} Epigenetics} |Shelf Life: ≥360 days if stored properly.{{Sirukumab} site|{Sirukumab} Interleukin Related|{Sirukumab} Protocol|{Sirukumab} In Vivo|{Sirukumab} custom synthesis|{Sirukumab} Autophagy} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:23514335 |Drug Formulation: To be determined.|HS Tariff Code: 382200|How to use|In Vitro:|EBOV/MARV-IN-1 (12.5 µM; 48 h) inhibits HIV/EBOV-GP (EC50=12 nM) and HIV/MARV-GP (EC50=180 nM) pseudotype virus in A549 cells containing a luciferase reporter gene, with low cytotoxicity (SI =2088).|References:|Gaisina IN, et, al. Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections. J Med Chem. 2020 Jul 9;63(13):7211-7225.Products are for research use only. Not for human use.|

Additional information:
YC-1 is a inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha). YC-1 is widely used as a potent inhibitor of HIF-1alpha both in vitro and in vivo, and is also being developed as a novel anticancer drug. YC-1 effectively inhibits tumor invasion and metastasis, and imply that YC-1 is worth while to further develop as a multipurpose anticancer drug.|Product information|CAS Number: 170632-47-0|Molecular Weight: 304.34|Formula: C19H16N2O2|Synonym:|Lificiguat|YC1|YC 1|YC-1|Chemical Name: 5-[1-(phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol|Smiles: OCC1=CC=C(O1)C1=NN(CC2C=CC=CC=2)C2=CC=CC=C21|InChiKey: OQQVFCKUDYMWGV-UHFFFAOYSA-N|InChi: InChI=1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2|Technical Data|Appearance: Solid Power.PMID:24463635 |Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO, not in water|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|References:|Tsui L, Fong TH, Wang IJ. The effect of 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole (YC-1) on cell viability under hypoxia. Mol Vis. 2013 Nov 16;19:2260-73. eCollection 2013. PubMed PMID: 24265542; PubMed Central PMCID: PMC3834593.Carroll CE, Liang Y, Benakanakere I, Besch-Williford C, Hyder SM. The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development. Int J Oncol. 2013 Jan;42(1):179-87. doi: 10.3892/ijo.2012.1675. Epub 2012 Oct 24. PubMed PMID: 23123638; PubMed Central PMCID: PMC3583650.Tsui L, Fong TH, Wang IJ. YC-1 targeting of hypoxia-inducible factor-1α reduces RGC-5 cell viability and inhibits cell proliferation. Mol Vis. 2012;18:1594-603. Epub 2012 Jun 15. PubMed PMID: 22736948; PubMed Central PMCID: PMC3380911.Products are for research use only. Not for human use.|

Additional information:
Ciraparantag (free base), also known as PER977, is a small molecule reversal agent for new oral anticoagulants and heparins. PER977 is a water-soluble, cationic molecule that is designed to bind specifically to unfractionated heparin and low-molecular-weight heparin through noncovalent hydrogen bonding and charge–charge interactions.|Product information|CAS Number: 1438492-26-2|Molecular Weight: 512.70|Formula: C22H48N12O2|Synonym:|PER977|PER-977|PER 977|Aripazine|Ciraparantag|Chemical Name: (2S,2’S)-N,N’-(piperazine-1,4-diylbis(propane-3,1-diyl))bis(2-amino-5-guanidinopentanamide)|Smiles: NC(=N)NCCC[C@H](N)C(=O)NCCCN1CCN(CC1)CCCNC(=O)[C@@H](N)CCCNC(N)=N|InChiKey: HRDUUSCYRPOMSO-ROUUACIJSA-N|InChi: InChI=1S/C22H48N12O2/c23-17(5-1-7-31-21(25)26)19(35)29-9-3-11-33-13-15-34(16-14-33)12-4-10-30-20(36)18(24)6-2-8-32-22(27)28/h17-18H,1-16,23-24H2,(H,29,35)(H,30,36)(H4,25,26,31)(H4,27,28,32)/t17-,18-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO, not in water|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|References:|Dzik WH. Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal. J Thromb Haemost. 2015 Jun;13 Suppl 1:S187-94. doi: 10.1111/jth.12949. PubMed PMID: 26149022.Crowther M, Crowther MA. Antidotes for Novel Oral Anticoagulants: Current Status and Future Potential.{{Nimodipine} MedChemExpress|{Nimodipine} Membrane Transporter/Ion Channel|{Nimodipine} Purity & Documentation|{Nimodipine} Data Sheet|{Nimodipine} supplier|{Nimodipine} Cancer} Arterioscler Thromb Vasc Biol.{{Biotin-PEG4-NHS ester} web|{Biotin-PEG4-NHS ester} PROTAC Linkers|{Biotin-PEG4-NHS ester} TGF-beta/Smad|{Biotin-PEG4-NHS ester} Technical Information|{Biotin-PEG4-NHS ester} References|{Biotin-PEG4-NHS ester} custom synthesis} 2015 Aug;35(8):1736-45.PMID:28739548 doi: 10.1161/ATVBAHA.114.303402. Epub 2015 Jun 18. PubMed PMID: 26088576.Sullivan DW Jr, Gad SC, Laulicht B, Bakhru S, Steiner S. Nonclinical Safety Assessment of PER977: A Small Molecule Reversal Agent for New Oral Anticoagulants and Heparins. Int J Toxicol. 2015 Jun 15. pii: 1091581815590667. [Epub ahead of print] PubMed PMID: 26079256.Mo Y, Yam FK. Recent advances in the development of specific antidotes for target-specific oral anticoagulants. Pharmacotherapy. 2015 Feb;35(2):198-207. doi: 10.1002/phar.1532. Epub 2015 Feb 3. PubMed PMID: 25644580.Yates SW. Interrupting anticoagulation in patients with nonvalvular atrial fibrillation. P T. 2014 Dec;39(12):858-80. PubMed PMID: 25516695; PubMed Central PMCID: PMC4264672.Products are for research use only. Not for human use.|

Additional information:
CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models . CB-5083 causes rapid and sustained accumulation of poly-ubiquitin in tumor xenografts after a single administration. CB-5083 showed activity to inhibit tumor growth in multiple rodent models of human cancer. Furthermore, CB-5083 appears to exhibit greater potency over current proteasome inhibitors that further validate targeting p97 and protein homeostasis in the treatment of cancer.|Product information|CAS Number: 1542705-92-9|Molecular Weight: 413.47|Formula: C24H23N5O2|Chemical Name: 1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide|Smiles: CC1=CC2C(=CC=CC=2C(N)=O)N1C1=NC2CCOCC=2C(NCC2C=CC=CC=2)=N1|InChiKey: RDALZZCKQFLGJP-UHFFFAOYSA-N|InChi: InChI=1S/C24H23N5O2/c1-15-12-18-17(22(25)30)8-5-9-21(18)29(15)24-27-20-10-11-31-14-19(20)23(28-24)26-13-16-6-3-2-4-7-16/h2-9,12H,10-11,13-14H2,1H3,(H2,25,30)(H,26,27,28)|Technical Data|Appearance: Solid Power.{{Carbamazepine} web|{Carbamazepine} Sodium Channel|{Carbamazepine} Technical Information|{Carbamazepine} In Vitro|{Carbamazepine} manufacturer|{Carbamazepine} Cancer} |Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO up to 100 mM|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Biotin-PEG4-NHS ester} web|{Biotin-PEG4-NHS ester} PROTAC Linkers|{Biotin-PEG4-NHS ester} Epigenetics|{Biotin-PEG4-NHS ester} Protocol|{Biotin-PEG4-NHS ester} References|{Biotin-PEG4-NHS ester} supplier} |Shelf Life: ≥12 months if stored properly.PMID:24914310 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|How to use|In Vitro:|CB-5083 was used at 1-2.5 µM final concentration in various assays.|In Vivo:|CB-5083 was dosed to mice orally at 25-100 mg/Kg once or twice per day.|References:|Zhou HJ, et al. Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083). (2015) J Med Chem. 58(24):9480-97.Products are for research use only. Not for human use.|Documents||